By Lina carolina 
Certain tumour types possess the dangerous ability to escape their site of origin and spread throughout the body, a process known as metastasis. This insidious spread is facilitated by the primary tumour continuously releasing cancer cells into the bloodstream. These circulating tumour cells (CTCs) can aggregate into small clusters, typically comprising up to a dozen cells, before lodging in distant organs. Once settled, these clusters proliferate into larger tumours, known as metastases, which are responsible for a staggering number of cancer-related deaths globally. Annually, approximately seven million individuals succumb to metastatic disease, underscoring its critical status as a major medical challenge.
The Pervasive Threat of Metastatic Breast Cancer
Breast cancer serves as a stark illustration of this metastatic phenomenon. The emergence of metastases from a primary breast tumour dramatically diminishes a patient’s prognosis. Despite advancements in treatment, tens of thousands of women worldwide continue to die from metastatic breast cancer each year. This grim reality fuels an urgent quest among oncologists to identify strategies that can weaken or dismantle these CTC clusters, thereby thwarting the development of secondary tumours.
A Novel Approach: Targeting CTC Clusters with Digoxin
In a significant development, a collaborative team of researchers from ETH Zurich, the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital has unveiled a promising new strategy. Their findings, recently published in the esteemed journal Nature Medicine, detail a clinical study involving nine patients diagnosed with metastatic breast cancer. For a period of one week, these patients were administered the drug digoxin at a low and clinically safe dosage.
The outcomes of this groundbreaking study have been profoundly encouraging. The research team observed a substantial decrease in the number of cells within each CTC cluster, with an average reduction of 2.2 cells. Considering that typical CTC clusters consist of only a handful of cells, this reduction represents a significant attenuation of the metastatic potential. The underlying principle is straightforward: smaller clusters are inherently less capable of successfully establishing secondary tumours. Professor Nicola Aceto, the principal investigator and a Professor of Molecular Oncology at ETH Zurich, articulated this critical insight: "Breast cancer metastasis depends on CTC clusters. The larger they are, the more successful they are."
The Molecular Mechanism: Unlocking the Achilles’ Heel of CTC Clusters
The vulnerability of CTC clusters lies in their reliance on sodium-potassium pumps, also known as Na+/K+-ATPases. These essential molecular machines are embedded within the cell membranes of tumour cells and are responsible for maintaining crucial ion gradients by actively transporting sodium ions out of the cell and potassium ions into it. Digoxin, in this context, acts as a potent inhibitor of these ion pumps. By blocking their activity, digoxin disrupts the delicate balance of ion exchange within the tumour cells. This disruption leads to an increased influx of calcium from the extracellular environment into the cell. The resulting surge in intracellular calcium weakens the cohesive forces that bind cancer cells together within a cluster, causing them to dissociate and fall apart.
It is crucial to note, however, that digoxin’s primary role in this therapeutic strategy is not to directly eliminate established tumours. Instead, its efficacy is maximized when administered in conjunction with other agents designed to specifically target and destroy existing cancer cells. This synergistic approach holds the potential to not only prevent the formation of new metastases but also to address the primary tumour burden.
A Journey of Discovery: From Plant to Precision Medicine
The journey to this innovative therapeutic avenue began with digoxin itself, an active ingredient historically derived from the foxglove plant (Digitalis sp.). For decades, digoxin has been a cornerstone in the treatment of various heart conditions, most notably heart failure, owing to its effects on cardiac muscle contractility. However, the potential of digoxin in the realm of oncology remained largely unexplored until a pivotal discovery by the ETH Zurich researchers in 2019.
In that year, Professor Aceto’s lab embarked on an extensive screening initiative. This systematic investigation involved testing over 2,400 different chemical compounds in cell culture models. The objective was to identify substances that exhibited activity against clusters of circulating tumour cells. This rigorous process of elimination and identification ultimately pinpointed digoxin as a promising candidate.
Future Directions: Optimizing Digoxin and Expanding its Reach
Building upon this foundational discovery, the ETH Zurich researchers are now focused on optimizing the therapeutic potential of digoxin. The next phase of their work involves the development of novel molecules that are structurally related to digoxin but possess enhanced efficacy in dissolving CTC clusters. This ambitious endeavor is being pursued through a dedicated ETH spin-off company, Page Therapeutics, which is actively engaged in the design and synthesis of these next-generation compounds.
Professor Aceto also harbours a broader vision for this research. He intends to extend the investigation into other cancer types that are known for their metastatic capabilities. This includes an array of challenging malignancies such as prostate cancer, colorectal cancer, pancreatic cancer, and melanoma. Initial laboratory experiments exploring the efficacy of digoxin-based strategies against CTCs from these diverse cancer types have already commenced, signalling a significant expansion of the research scope.
The success of this study is a testament to the power of interdisciplinary collaboration. The seamless partnership between ETH Zurich and its hospital counterparts – the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital – was instrumental in bringing this research to fruition. The hospital partners played a vital role in recruiting patients and meticulously conducting the clinical trials, thereby bridging the critical gap between laboratory discovery and real-world patient care. This collaborative model serves as a compelling example of how academic institutions and clinical facilities can unite to drive medical innovation forward.
Broader Implications and the Evolving Landscape of Cancer Treatment
The implications of this research extend far beyond the immediate impact on breast cancer patients. The successful targeting of CTC clusters represents a paradigm shift in how we approach the prevention and treatment of metastasis. For decades, the focus has largely been on eradicating the primary tumour and managing existing metastatic disease. This new approach offers the tantalizing prospect of intercepting cancer’s spread at a much earlier, and potentially more vulnerable, stage.
The development of digoxin-based agents designed to dismantle CTC clusters could revolutionize cancer therapy by:
- Reducing the incidence of metastasis: By preventing CTCs from forming stable clusters and successfully implanting in distant organs, the formation of secondary tumours could be significantly curtailed. This would translate into improved survival rates and a better quality of life for patients.
- Enhancing the efficacy of existing treatments: When combined with conventional therapies such as chemotherapy or immunotherapy, digoxin-based agents could create a more potent anti-cancer attack. By weakening the metastatic potential of cancer cells, they might make them more susceptible to other forms of treatment.
- Offering new hope for advanced cancers: For patients with advanced or metastatic disease, where treatment options are often limited, the ability to disrupt the spread of cancer could offer a much-needed new avenue of hope.
The historical context of digoxin, a well-established drug with a known safety profile, also adds a layer of pragmatic optimism to this research. While the development of new molecules by Page Therapeutics is crucial for optimizing efficacy, the existing understanding of digoxin’s pharmacology and toxicology can expedite the translation of these findings into clinical practice.
Furthermore, the expansion of this research to other cancer types suggests a potential for broad applicability. Metastasis is a common hallmark of many aggressive cancers, and a therapy that can effectively target the mechanisms of spread could have a transformative impact across a wide spectrum of oncological challenges.
The Road Ahead: Challenges and Opportunities
Despite the encouraging early results, several challenges lie ahead. The clinical trials thus far have involved a small cohort of patients, and larger, more comprehensive studies will be necessary to confirm the efficacy and safety of digoxin in treating metastatic breast cancer and potentially other cancers. Understanding the optimal dosage, treatment duration, and potential long-term side effects will be critical.
Moreover, the development of resistance to digoxin or related compounds is a possibility that will need to be carefully monitored. Cancer cells are notoriously adept at evolving and evading therapeutic interventions. Therefore, ongoing research into the mechanisms of resistance and the development of combination therapies that circumvent these mechanisms will be paramount.
The scientific community will be closely watching the progress of Page Therapeutics and Professor Aceto’s laboratory. The successful translation of these promising laboratory findings and early clinical results into approved therapies would mark a significant milestone in the fight against cancer. It would underscore the importance of fundamental research in uncovering novel therapeutic targets and highlight the power of collaborative efforts between academia and industry to bring life-saving innovations to patients. The journey from the foxglove plant to a potential weapon against cancer metastasis is a compelling narrative of scientific curiosity, perseverance, and the unwavering commitment to alleviating human suffering. The ongoing research into digoxin and its derivatives represents a beacon of hope for millions worldwide grappling with the devastating consequences of metastatic disease.
